S 1930 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
To amend title XI of the Social Security Act to establish a research and development-intensive small biotech manufacturer exception from the Medicare drug price negotiation program.
Summary
This bill creates an exception from Medicare's drug price negotiation program for research and development-intensive small biotech manufacturers, beginning in 2029. It defines eligible manufacturers as those with five or fewer drugs that invest a specified percentage of their net revenue in research and development, with the required R&D percentage ranging from 30 to 70 percent depending on how many qualifying drugs they have. Qualifying drugs from these manufacturers would be excluded from Medicare price negotiations. The bill requires manufacturers to submit annual applications with financial information to demonstrate they meet the criteria, and it includes a dispute resolution process for manufacturers to appeal determinations.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
- Sen. Cassidy, Bill [R-LA] (R-LA)
1 cosponsor
- Sen. Marshall, Roger [R-KS] (R-KS)
Money behind the sponsor
Top reported contributors to Bill Cassidy’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- ANDREESSEN HOROWITZ $59,100
- GENERAL ATLANTIC $37,700
- WELSH CARSON ANDERSON & STOWE $33,870
- OCHSNER HEALTH SYSTEM $33,250
- RA CAPITAL MANAGEMENT $30,200
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Bill Cassidy → · Outside spending →
Actions (2)
- Jun 3, 2025 Read twice and referred to the Committee on Finance. · senate
- Jun 3, 2025 Introduced in Senate
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Full text
IN THE SENATE OF THE UNITED STATES
June 3, 2025
Mr. Cassidy introduced the following bill; which was read twice and referred to the Committee on Finance
A BILL
To amend title XI of the Social Security Act to establish a research and development-intensive small biotech manufacturer exception from the Medicare drug price negotiation program.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Small Biotech Innovation Act”.
SEC. 2. RESEARCH AND DEVELOPMENT-INTENSIVE SMALL BIOTECH MANUFACTURER EXCEPTION FROM MEDICARE DRUG PRICE NEGOTIATION PROGRAM.
Section 1192(d)(2) of the Social Security Act (42 U.S.C. 1320f- 1(d)(2)) is amended by adding at the end the following new subparagraph:
“(D) Research and development-intensive small biotech manufacturer exception for 2029 and subsequent years.—
“(i) In general.—With respect to initial price applicability years (beginning with initial price applicability year 2029), subject to the succeeding provisions of this subparagraph, the term ‘negotiation eligible drug’ shall not include a qualifying single source drug (as defined in subsection (e)) of a research and development-intensive small biotech manufacturer (as defined in clause
(ii)).
“(ii) Definitions.—In this subparagraph:
“(I) Applicable percent.—The term ‘applicable percent’ means— “(aa) in the case of a small biotech manufacturer that has 1 qualifying single source drug, 30 percent; “(bb) in the case of a small biotech manufacturer that has 2 qualifying single source drugs, 40 percent;
“(cc) in the case of a small biotech manufacturer that has 3 qualifying single source drugs, 50 percent;
“(dd) in the case of a small biotech manufacturer that has 4 qualifying single source drugs, 60 percent; and “(ee) in the case of a small biotech manufacturer that has 5 qualifying single source drugs, 70 percent.
“(II) Small biotech manufacturer defined.—The term ‘small biotech manufacturer’ means a manufacturer that— “(aa) has 5 or less qualifying single source drugs; and “(bb) is not owned by, controlled by, or subject to the jurisdiction or direction of a government of a foreign country, or organized under the laws of a foreign country that is a covered nation (as defined in section 4872(f) of title 10, United States Code).
“(III) Research and development- intensive small biotech manufacturer defined.—The term ‘research and development-intensive small biotech manufacturer’ means a small biotech manufacturer that invests at least the applicable percent of their net revenue from the average of the previous three years in research and development (determined based on generally accepted accounting principles).
“(iii) Treatment in case of acquisition.— A drug shall not be considered to be a qualifying single source drug of a research and development-intensive small biotech manufacturer if the manufacturer of such drug is acquired after 2029 by another manufacturer that does not meet the definition of a research and development-intensive small biotech manufacturer, effective at the beginning of the plan year immediately following such acquisition.
“(iv) Annual application.—In order for a qualifying single source drug of a research and development-intensive small biotech manufacturer to be eligible for the exception under this subparagraph with respect to an initial price applicability year (beginning with initial price applicability year 2029), the manufacturer shall submit an application to the Secretary (at a time specified by the Secretary) containing—
“(I) information on the net product revenue and research and development expenditures of the manufacturer during the relevant time period;
“(II) a certification that the information submitted by the manufacturer under subclause (I) is accurate and complete to the best of the manufacturer’s knowledge; and
“(III) such other information as the Secretary may specify.
“(v) Dispute resolution.—The Secretary shall develop a process under which a manufacturer may appeal a determination by the Secretary that the manufacturer is not a research and development-intensive small biotech manufacturer. Such process shall conclude, with respect to a manufacturer, not later than the selected drug publication date with respect to the initial price applicability year for which the manufacturer submitted an application under clause (iv).”. <all>
Comments